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Differential expression of CK20, β-catenin,
and MUC2/5AC/6 in Lynch syndrome and
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Abstract
Background: Hereditary non-polyposis colorectal cancer comprises Lynch syndrome and familial colorectal cancer
type X (FCCTX). Differences in genetics, demographics and histopathology have been extensively studied. The
purpose of this study is to characterize their immunoprofile of markers other than MMR proteins.
Methods: We compared the expression patterns of cytokeratins (CK7 and CK20), mucins (MUC2/5 AC/6), CDX2 and
β-catenin in Lynch syndrome and FCCTX.
Results: Differences were identified for CK20 and nuclear β-catenin, which were significantly more often expressed
in FCCTX than in Lynch syndrome (p < 0.001), whereas MUC2, MUC5AC and MUC6 were overexpressed in Lynch
syndrome tumors compared with FCCTX tumors (p = 0.001, < 0.01, and < 0.001, respectively). We observed no
differences in the expression patterns of CK7 and CDX2.
Conclusions: In summary, we identified significant differences in the immunoprofiles of colorectal cancers linked to
FCCTX and Lynch syndrome with a more sporadic-like profile in the former group and a more distinct profile with
frequent MUC6 positivity in the latter group.
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Background
Identification of hereditary colorectal cancer provides an
unprecedented possibility for cancer prevention through
inclusion of family members at increased risk into surveil-
lance programs. Identification and diagnostics of heredi-
tary colorectal cancer requires joint efforts from clinicians,
pathologists and geneticists. Hereditary non-polyposis
colorectal cancer (HNPCC) represents the most common
subset of hereditary colorectal cancer and comprises the
major subsets Lynch syndrome and familial colorectal
cancer type X (FCCTX). Germline mutations in one of
the mismatch repair (MMR) genes and resultant microsat-
ellite instability (MSI) characterize Lynch syndrome,
whereas retained MMR function and unknown genetic
causes characterize FCCTX [1–3]. Lynch syndrome shows
a lower mean age at onset, an abundance of right-sided
colon tumors and more frequent extracolonic tumors,
whereas FCCTX is predominantly characterized by tu-
mors in the distal colon and the rectum and shows a
somewhat higher mean age at onset. Histologic differences
include a “pushing” growth pattern, lymphocytic reactions,
poor differentiation with mucinous and medullary growth
patterns in Lynch syndrome and an infiltrative growth
pattern, tumor budding, “dirty” necrosis, glandular differ-
entiation and frequent node positivity in FCCTX [4–6].
The purpose of this study is to record the immunopro-
file of markers well-described in colorectal carcinoma in
general but, hitherto, incompletely studied in hereditary
colorectal carcinomas. These include cytokeratins, mucin
glycoproteins, and CDX2. Specifically, its discriminatory
utility in FCCTX- vs Lynch syndrome cases is addressed,
as is the feasibility of identifying FCCTX among colorectal
carcinomas in general. Additionally, β-catenin is included,
to compare the extent of the wnt pathway activation in
the two hereditary cohorts, as Wnt-signaling genes are
shown to be upregulated in FCCTX tumors.
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Methods
Patient identification and accrual of samples
Patients were identified through the national Danish
HNPCC register (http://www.hnpcc.dk). In Denmark,
patients with suspected or verified hereditary colorectal
cancer are reported to this register by laboratories and
responsible clinicians. In Denmark, colorectal cancer
diagnostics includes reflex testing for MMR protein ex-
pression using antibodies against MLH1, PSM2, MSH2
and MSH6. Cases with loss of expression are, if applic-
able, and implying the patient provides consent, referred
to genetic counselling. Genetic counselling is performed
by clinical genetic counsellors and clinical geneticists at
4 departments countrywide. Following genetic diagnos-
tics, Lynch syndrome was defined as presence of
disease-predisposing MMR gene variants (classes 4 and
5) and FCCTX was defined as families that fulfilled the
Amsterdam criteria, but had tumors with retained MMR
function and for the majority of families also genetic
MMR gene testing without mutations. The histopatho-
logical profiles of the 2 cohorts have been presented in
Klarskov et al. [4]. In total, 65 colorectal cancers from
60 individuals in 41 FCCTX families and 68 Lynch syn-
drome tumors from 62 individuals in 41 families were
studied including 2 synchronous and 3 metachronous
tumor pairs. Hematoxylin & eosin stained slides from
the formalin fixed-paraffin embedded (FFPE) tissue sam-
ples selected were reviewed to ensure representation of
the deep tumor margin [7]. Clinical data were collected
from the pathology reports and tumor location was classi-
fied as proximal or distal in relation to the splenic flexure.
Tumor differentiation was classified as poorly differenti-
ated/undifferentiated or highly/moderately differentiated.
The study was granted ethical permission by the Re-
gion Hovedstaden ethical review board (H-D-2007-032).
Immunohistochemical staining
Immunohistochemical stainings were performed on fresh
4-μm sections from FFPE tissue that was deparaffinized in
Tissue clear. Antigen retrieval was achieved by PT-Link
and 3-in-1 buffer, pH 9 (Dako). The sections were proc-
essed in a Dako autostainer (Dako, Denmark), applying
the antibodies targeting CK7/20, MUC2/5 AC/6, CDX2,
and β-catenin (Table 1). The Envision Detection Kit
(DakoCytomation) was used according to the manufac-
turer’s instructions and tissue sections were counter-
stained with Meyer’s hematoxylin, dehydrated, mounted
on coated slides, and dried 1 h at 60°. The immunostain-
ings were scored semiquantitatively by two independent
pathologists (LK, SH), blinded to mutational status. A 5-
tier scale was applied, using the following categories; no
staining, < 5%, 5–50%, 51–95% and > 95% stained tumor
cells. In the analyses, the stainings were dichotomized into
negative (< 5% staining) and positive (≥ 5% staining). For
CDX2 only strong expression, equivalent to the intensity
of the normal mucosa was considered, for the other
immunostainings, labelling intensity was not considered.
Where interpretative doubts arose and in case of diverse
readings, which rarely exceeded one category, consensus
was reached by conference.
Statistics
All data were entered in duplicate in Epidata and exported
to SPSS 17.0 for statistical analysis. Statistical differences
between the groups were determined using Pearson’s χ2-
test for categorical and independent samples, t-test for
continuous parametric data. P-values less than 0.05 were
considered statistically significant.
Results
Clinical data
Clinical data are summarized in Table 2. Significant differ-
ences applied as regards age (younger mean age in Lynch
syndrome, p < 0.001), tumor location (78% of FCCTX
tumors were left-sided versus 26% of Lynch syndrome,
p < 0.001) and extent of differentiation (54% of Lynch
syndrome poorly differentiated/undifferentiated versus 17%
of FCCTX tumors (p < 0.001)).
Table 1 Antibodies
Antibody Clone Dilution Manufacturer
CK7 OV-TL 12/30 RTU Dako, DK
CK20 KS20.8 RTU Dako, DK
MUC2 Ccp58 1:25 Novocastra/Leica, UK
MUC5Ac CLH2 1:200 Novocastra/Leica, UK
MUC6 CLH5 1:50 Novocastra/Leica, UK
β-catenin β-catenin 1 RTU Dako, DK
Cdx2 Dak-CDX2 RTU Dako, DK
RTU ready to use
Table 2 Demographics and tumor differentiation
Variables FCCTX (n = 65) Lynch (n = 68) P value
Median age, (range), years 60 (28–83) 52 (25–82) < 0.001
Gender, male 34 (52%) 28 (41%) NS
Tumor sitea < 0.001
Right 13 (20%) 48 (71%)
Left 51 (78%) 18 (26%)
Not indicated 1 (2%) 2 (3%)
Histological differentiation < 0.001
High/moderate 54 (83%) 31 (56%)
Poor/undifferentiated 11 (17%) 37 (54%)
NS not significant
aCut-off: splenic flexure
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Immunohistochemistry
The immunohistochemical profiles for five of the seven
markers studied significantly differed between colorectal
cancers linked to FCCTX and Lynch syndrome (Tables 3
and 4). Aberrant, nuclear staining for β-catenin (Fig. 1a)
was more common in FCCTX tumors, whereas the β-
catenin staining more often was normal, i.e. confined to
the cell membranes (Fig. 1b), in Lynch syndrome
(p < 0.001). Compared to FCCTX tumors, Lynch syn-
drome tumors displayed significantly more often expres-
sion of the tested MUC glycoproteins. The difference in
MUC expression was particularly prominent for MUC6
(Fig. 2) (p < 0.001), less so for MUC2 (Fig. 3) (p = 0.001),
and MUC5AC (p < 0.01). FCCTX tumors showed more
frequent CK20 expression than did Lynch syndrome tu-
mors (p < 0.001) with an equal distribution in right and
left side of the large bowel. In Lynch syndrome tumors,
CK20 expression patterns correlated to tumor location
with more frequent expression of CK20 in right-sided tu-
mors (77%) than in the left-sided tumors (50%) (p = 0.03).
The CK7 expression rate was 12 and 15% in FCCTX
and Lynch syndrome, respectively.
The combined CK7/20 patterns showed significant dif-
ferences between Lynch syndrome tumors and FCCTX
tumors (Table 4). The prevailing CK7−/CK20+ profile
was identified in 83% of the FCCTX cases and in 63% of
the Lynch syndrome tumors. CK7+/CK20+ profile was
the second most common combination (12%) in
FCCTXs, but was rare (4%) in Lynch syndrome tumors,
which more often (22%) showed a CK7−/CK20- profile.
Expression of CDX2 was abundant without statistical
significant differences between Lynch syndrome and
FCCTX (93 and 99%, respectively).
Discussion
Immunohistochemical staining is commonly applied as
adjunct diagnostics in colorectal cancer. To this end
profiles for the expression of cytokeratins, CDX2 and
mucin glycoproteins are well-established markers [8–11]
that are available in colorectal cancer diagnostics in
most pathology laboratories. Since application of such
profiles may be relevant also in hereditary cancer diag-
nostics, our aim was to define these profiles in the two
major HNPCC subsets of colorectal cancer. Moreover,
immunohistochemical profiling may contribute to the
molecular understanding of these subsets. Herein, a
large fraction of FCCTX tumors has been shown to
harbour APC (adenomatous polyposis coli) mutations
[12], which motivated evaluation of β-catenin staining as
a candidate marker.
Tumors linked to Lynch syndrome and FCCTX showed
significant differences, primarily related to frequent ex-
pression of CK20 and nuclear β-catenin in FCCTX and
relative over-expression of MUC2, MUC5AC and MUC6
in Lynch syndrome. Sánchez-Tomé et al. likewise reported
differences in the immunoprofile of FCCTX carcinomas
(27 cases) – and Lynch syndrome carcinomas (18 cases)
based on markers selected to analyze colorectal carcino-
genesis, including SMAD4, COX2, MUC1, and P53 [13].
Despite differences in the selected immunopanels in these
two studies the differences between the two hereditary co-
horts in both studies are remarkable, and suggest that
these profiles may be of clinical diagnostic relevance. We
further found that FCCTX tumors generally mimicked the
profile of the non-neoplastic colorectal mucosa, with
CK20+, MUC5AC- and MUC6-, which contrasted to the
expression pattern in the Lynch syndrome tumors.
Frequent (70–100%) expression of CK20 has been re-
ported in unselected colorectal cancers [8, 14–20]. The
reduced expression of CK20 observed in Lynch syn-
drome is in line with reduced CK20 levels in MSI tu-
mors [9] and in poorly differentiated tumors (54% of
Lynch syndrome carcinomas vs 17% in the FCCTX cases
in the present material were poorly differentiated). In
this context, it is noteworthy that cytokeratin filaments
are relatively stable during transformation to carcinoma
[21], a quality that is lost in a proportion of the Lynch
syndrome carcinomas. CK20 expression has also been
reported to correlate with the anatomical location with
more abundant expression in the distal colon [17, 22].
This distribution pattern was, however, not observed in
the current cohorts, which showed no side differences in
FCCTX and higher expression in proximal than in distal
Lynch syndrome tumors.
Table 3 Immunoprofiles of FCCTX and Lynch syndrome-
associated CRC
Marker FCCTX (n = 65) Lynch (n = 68) P value
CK20, n (%) 62 (95) 46 (68) < 0.001
CK7, n (%) 8 (12) 10 (15) NS
MUC2, n (%) 42 (65) 60 (88) 0.001
MUC5AC, n (%) 7 (11) 20 (29) < 0.01
MUC6, n (%) 2 (3) 17 (25) < 0.001
CDX2, n (%) 64 (99) 63 (93) NS
β-catenin, nuclear, n (%) 34 (52) 11 (16) < 0.001
NS not significant
Table 4 Combined CK7/CK20-profiles of FCCTX and Lynch
syndrome-associated CRC
Combination FCCTX (n = 65) Lynch (n = 68) P value
CK7−/CK20+, n (%) 54 (83) 43 (63) 0.01
CK7+/CK20+, n (%) 8 (12) 3 (4) NS
CK7−/CK20-, n (%) 3 (5) 15 (22) 0.003
CK7+/CK20-, n (%) 0 (0) 7 (10) 0.008
NS not significant
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CK7 expression did not differ between Lynch syn-
drome tumors and FCCTX tumors and paralleled the
expression levels (10–22%) in unselected and sporadic
colorectal cancers reported in the literature [8, 15, 17].
The prevailing CK7−/CK20+ cytokeratin profile is re-
ported in 55–77% of colorectal cancer in general [9] and
was also the predominant profile in the hereditary sub-
sets, though more frequent in FCCTX compared to
Lynch syndrome. The second most common cytokeratin
profile in unselected tumors is the CK7+/CK20+ com-
bination identified in 15% of tumors [8, 9, 23]. This pat-
tern was also the second leading profile in the FCCTX
cases. In Lynch syndrome tumors the CK7−/CK20- pro-
file was the second most common pattern, conceivably
reflecting a higher frequency of poorly differentiated tu-
mors [4, 24], speculatively a result of the hypermutated
state of MSI tumors. Of further note is the CK7+/20-
combination in 10% of our Lynch syndrome tumors.
Bayrak et al. [8] reported this rare pattern in only 2% of
unselected cases, whereas this profile specifically was
noted in high grade, right-sided colorectal cancers, prop-
erties suggestive of Lynch syndrome. According to our
results, this unusual profile seems to exclude FCCTX
and might suggest Lynch syndrome. Additionally, the
CK7−/20- combination makes FCCTX unlikely. The
other combinations of CK7 and CK20 lack, however, dis-
criminatory value.
Loss of expression of CDX2 in colorectal cancer has
been reported as a negative prognostic marker [25].
CDX2 expression in the HNPCC-associated colorectal
cancers in the present study was high, which is in ac-
cordance with the relatively good prognosis characteriz-
ing these cancers, and did not differ from some series on
colorectal carcinoma in general [23, 26–28]. Diversities
in study design, specifically use of tissue micro array,
can readily contribute to the lower values noted in other
reports of colorectal cancers [15, 29, 30].
Our study on the secreted gel-forming mucins
(MUC2, MUC5AC, and MUC6) demonstrated signifi-
cantly higher values in the Lynch syndrome than in the
FCCTX tumors. In this context, the idea that the MSI
status may influence mucus production, by altering the
genes involved [31] is noteworthy. Mucinous differenti-
ation, though it may not reach the 50% required for
Fig. 1 β-catenin expression in a FCCTX carcinoma (a) and in a Lynch syndrome carcinoma (b): The invasive front of FCCTX carcinoma (a) with
prominent nuclear labelling of the single, budding tumor cells (some are arrowed) and in most tumor cells sited in the more coherent group.
This aberrant profile characterized 52% of the FCCTX cohort, but only 16% of the Lynch syndrome tumors. Note additionally the infiltrative quality
of the invasive front of the tumor, another feature of FCCTX tumors [4]. The invasive front of a Lynch syndrome carcinoma (b) with normal
staining pattern, i.e. labelling confined to the tumor cell membranes, specifically absence of nuclear labelling. Note the pushing quality of the
invasive border (below) and absence of budding cells, additional features of Lynch syndrome carcinomas [4]
Fig. 2 Focal MUC6 expression in two LS carcinomas (a and b): 25% of the Lynch syndrome carcinomas were focally positive. This profile was
noted in highly/moderately differentiated examples (prominent glandular component) (a), as well as in poorly differentiated/undifferentiated
cases (absence of glandular elements) (b). Merely 3% of the FCCTX cohort displayed MUC6 expression
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classification of a mucinous tumor, is frequent in Lynch
syndrome tumors. Of note is the observation that MUC
expression levels identified in Lynch syndrome tumors
were higher than described in reported series of mucin-
ous tumors [32–34]. MUC6 expression has been sug-
gested to inhibit tumor invasion in pancreatic cancer
[35], which may apply to colorectal cancer as well and
could play a role in the favourable prognosis known to
characterize Lynch syndrome tumors. Indeed, a recent
report on the clinical significance of secreted gel-
forming MUCs in colorectal carcinomas demonstrated a
favorable influence on the outcome in case of gain in ab-
errant MUC expression, particularly of MUC6 expres-
sion [36]. The MUC profile in the FCCTX subset was
more akin to that of unselected colorectal cancers with
MUC2 expression reported in 40–54%, MUC5AC in 6–
10% and MUC6 in 4% [17, 37].
Nuclear translocation of β-catenin is a marker of dys-
regulated Wnt signalling. Diverse mechanisms may in-
duce this event in colorectal carcinoma, the major cause
being dysfunction of the APC gene [38]. In total, 52% of
the present FCCTX tumors showed aberrant nuclear β-
catenin, which is in line with unselected and MMR-
proficient series [26, 39]. The findings also roughly cor-
relate with those of Franscisco et al. [12] who reported
APC mutation in 62% of their FCCTX cases. Other
MMR-mutation negative, familial series (including 20,
24, and 44 cases) have reported lower frequencies of nu-
clear β-catenin [40–42]. Given the presumed heterogen-
eity of FCCTX tumors, partial inclusion of MSI tumors,
differences in study design and limited-size series dispar-
ities can be anticipated [12]. β-catenin mutation, another
cause of aberrant β-catenin, probably contributes to the
occasional aberrant β-catenin expression in Lynch syn-
drome tumors. Based on the current immunohistochem-
ical study, nuclear β-catenin expression in Lynch
syndrome tumors is uncommon compared to its preva-
lence in FCCTX (16% vs. 52%). In concert, nuclear β-
catenin expression was previously recorded in merely
19% of colorectal cancer from 118 Lynch syndrome pa-
tients in a study conducted by some of us [43]. Further
markers of the wnt-signalling pathway may be of interest
in future studies of FCCTX tumors.
Distinct gene expression patterns have been demon-
strated in colorectal cancers linked to Lynch syndrome
and FCCTX and overall support that FCCTX tumors
mimic sporadic MMR-proficient tumors [44, 45]. These
data and the immunohistochemical expression differ-
ences we describe herein suggest that evaluation of key
markers should be exploited for future diagnostic appli-
cation. FCCTX tumors are characterized by chromo-
somal instability and deregulation of genes and proteins
involved in e.g. chromosomal segregation, genomic sta-
bility, apoptosis, proliferation, growth inhibition, angio-
genesis and migration [44]. The limited data available
point to involvement of pathways related to G protein-
coupled signaling, proliferation and migration. In line
with this, FCCTX tumors frequently show infiltrative
growth patterns and presence of dirty necrosis [45].
Lynch syndrome tumors show frequent deregulation of
genes involved in the cell cycle progression and in the
oxidative phosphorylation pathway as well as immune
response genes. Regarding the latter, studies are cur-
rently exploring the role of immunohistochemical evalu-
ation of specific immune checkpoint proteins in the
context of immunotherapy in colorectal cancer. The role
for DNA methylation changes remains to be defined,
though the gene-specific methylation of MLH1 is a hall-
mark of the hypermutable phenotype in sporadic MSI
tumors and global hypomethylation has been demon-
strated in FCCTX and has been shown to interfere with
chromosomal instability.
The strengths of the present study include clinically
well-defined and relatively large study populations, im-
munohistochemical evaluations on whole sections in
contraposition to the limited areas available by tissue
micro arrays (the latter a potential source of error, as
previously pinpointed [23]), and evaluation by two
Fig. 3 MUC2 expression in a Lynch syndrome carcinoma (a) and in a FCCTX carcinoma (b): 88% of the Lynch syndrome carcinomas were MUC2
positive, compared to 65% of the FCCTX cases. The Lynch syndrome carcinoma illustrated in A, is extensively decorated (portions of non-neoplastic
crypts appear to the right). The FCCTX carcinoma, illustrated in B, comprises only few scattered immunopositive cells. Top of the field displays basis of
several non-neoplastic crypts
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pathologists who were blinded to patient data. The study
design allows for descriptive analyses only, which is a
limitation and data on somatic mutations of KRAS,
NRAS and BRAF are not included.
Conclusions
Significant differences in the immunohistochemical pro-
files of colorectal cancers linked to Lynch syndrome and
FCCTX are not restricted to MMR-proteins. In particular,
CK20, MUC2, MUC5AC, MUC6 and β-catenin showed
disparate expression patterns that may in part be ascribed
to clinicopathologic factors such as tumor location,
mucinous components, differentiation, and MSI-status,
conceivably reflecting diverse underlying genetic mecha-
nism(s). The chosen antibody panel did not allow differen-
tiation between FCCTX and colorectal carcinoma in
general. As knowledge on FCCTX genetic(s) emerges,
translation into novel biomarkers, useful in discriminating
FCCTX from its sporadic counterpart can be anticipated.
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